St James’s Institute of Oncology, a radiotherapy center in the UK, recently ordered two Versa HD systems. The system delivers conventional therapies to a wide range of tumors throughout the body, while also permitting treatment of complex cancers that require extreme targeting accuracy.
St James’s investigators performed extensive clinical studies with High Dose Rate mode and Elekta’s 160-leaf multileaf collimator, both critical components of Versa HD. The combination of Agility with its rapid leaf speeds and High Dose Rate mode enables rapid delivery of the radiation dose, enabling faster treatments. In their clinical studies of these integrated technologies, St James’s researchers achieved substantial reductions in treatment times.
St James’s clinicians foresee a role for Versa HD in the treatment of inoperable lung cancer. The clinic has used hypofractionated lung stereotactic radiation therapy (SRT) since 2009, employing its Elekta technology extensively for these patients. Now, with Versa HD, St James’s hopes to use the system’s speed to further limit the likelihood of patient movement during treatment, thereby improving the accuracy and safety of SRT.
